Audit: QRS - Fadogia agrestis to Improve Testosterone
Audit conducted on 14/09/2026 06:06 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol doses (ER 286-292), time-to-effect (ER 149, 341), benefit and risk headings (ER 143-165, 197-219), gates (ER 237-262), all 12 biomarkers and cadence (ER 365-380), qualitative markers (ER 384-388). All literally supported. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing carried through verbatim: “no human timeline exists”, “no human sexual-function trial exists”, “No human data on dose timing exist”, “The benefit remains a hypothesis”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening detected; the speculative tier and rodent-only framing are preserved on every surface. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER “Populations who should avoid” list, Key Interactions from the ER interaction bullets, benefits and risks from their own ER sections. No cross-category relabelling. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, study citations, expert names, NCT identifiers or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s sober, evidence-limited register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert, objective and data-driven; the negative weighting is the ER’s own and is stated without alarm. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents thresholds and panels as information, not as orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive constructions; the footer disclaimer is template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise” or “you should” constructions anywhere in the file. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns present (verified across the whole file). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; technical marker names carry their ER expansions (LH, FSH, SHBG, GGT, PSA, MDA). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every cell is a compressed phrase; no narrative prose outside the 56-word lede. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed - no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes a reader running baseline panels, cycling and sourcing by certificate of analysis. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The 12-marker panel and fixed cadence presume willingness to follow an effortful protocol. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at the general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk-benefit weighting mirrors the ER: unproven benefit set against rodent organ signals and product variability. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal register throughout; “dose” is used where the ER said “capsule” in the cadence line. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Verified against the template: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, tier labels and “Marker”/”Target”/”Why” headers are all byte-identical. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names are present; marker_#* is expanded to marker_1..marker_12 and qualitative_item# to items 1-5, as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Every span in the file is addressed by a checklist item. The non-variable template elements (website=”evidence_review”, website=”audit”, website=”full_review”, footer disclaimer) and the entire inline stylesheet are unchanged from the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section mapped to a QRS variable is empty while carrying an ER empty-state phrasing. The empty benefit and risk tiers are governed by the more specific items 12.5 and 13.5, which mandate display:none rather than empty-state text. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Standard dose”, “Conservative dose anchored to the animal data” and “Time of day” are the ER’s bold labels verbatim; gate items reuse the ER’s bold interaction labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Biomarker names, protocol labels and tier labels are all verbatim; no invented labels. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters anywhere in the file (verified by codepoint scan); the ER’s tier and conflict emoji were correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to phrase-level content - drug lists trimmed to three examples, benefit and risk tiers collapsed to single comma-separated lines, marker rationales kept to one clause. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14: the metadata comment is the first element after <!doctype html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening — at line 3, closing — at line 13; the preceding “QRS - Metadata” text sits outside the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; not echoed by any visible element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: “00:04” is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: fadogia_agrestis_testosterone_2026-0914-0450_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0914-0600, correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed - see 5.4. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Fadogia agrestis to Improve Testosterone - Quick Reference Sheet”; the canonical_topic contains no characters needing entity encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417 matches the ER canonical_topic exactly. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/14/2026, the correct MM/DD/YYYY rendering of 2026-0914-0600. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5 |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; no badge, AKA line or variant marker, despite the ER listing three alternate names. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 408-414) into identity, evidence state, safety signal, product variability and verdict. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words, under the 60-word cap. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the five statements maps to a distinct Conclusion passage: ER 408 (shrub, animal-only), 408 (no human trial), 410 (organ strain), 412 (product variability), 414 (hypothesis). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; plain terms used throughout (“animal work”, “cellular strain”, “published trial”). |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER “Populations who should avoid Fadogia agrestis” list inside Key Interactions & Contraindications (ER 253-262). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER avoid-population bullets are present, in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the stop_items span, lines 567-574. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationale stripped where the ER carried it, e.g. “Men actively pursuing conception, given the rodent testicular findings” reduced to “Men actively pursuing conception”. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds preserved: 1.5x upper reference limit, eGFR below 60 mL/min/1.73 m2, PSA above 4 ng/mL, haematocrit above 52%, age under 18. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify avoid-populations, so the constraint holds. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER Key Interactions & Contraindications bullets (ER 237-251). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight ER interaction bullets are present, in ER order; none duplicates a contraindication entry. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the caution_items span, lines 582-589. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All mechanistic rationale and mitigation text stripped; each item is the ER bold label plus its example list. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved and trimmed to three names each per the one-page budget; none dropped entirely. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does identify interactions, so the constraint holds. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Drawn from the ER Therapeutic Protocol section (ER 284-306). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard dose, conservative dose anchored to the animal data, and time of day are the three actionable bullets in that section; the remainder (half-life unknown, no female protocol, no pharmacogenetic guidance) are non-actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content; values 300-600 mg daily, ~200 mg and Morning all trace to ER 286, 288 and 292. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Serum testosterone rise (ER 341), sexual motivation and performance (ER 149) and the eight-week follow-up panel (ER 341) are the only time-to-effect statements in the ER. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered to match the ER’s own benefit ranking within the Speculative tier: elevated serum testosterone first, sexual motivation second, with the monitoring milestone last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content with the rodent-only caveat attached to each. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Drawn from the ER Expected Benefits section (ER 127-165). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 539-557. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The six items are the ER’s H4 benefit headings reduced to bare noun phrases, with no bases, magnitudes or citations. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER headings carry no parentheses; the conflict and not-central markers were correctly dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high, benefits_medium and benefits_low all carry style=”display: none” with an HTML comment recording the ER basis; no empty-state text is rendered. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Drawn from the ER Potential Risks & Side Effects section (ER 181-219). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 601-619. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The six items are the ER’s H4 risk headings reduced to bare noun phrases, with no net statements or study detail. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The parenthetical in the ER heading “Erythrocytosis (Thickened Blood)” is stripped, leaving “erythrocytosis”. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high, risks_medium and risks_low all carry style=”display: none” with an HTML comment recording the ER basis. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER Monitoring Protocol & Defining Success section (ER 363-380). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 12 rows of the ER biomarker table are present with names, targets and rationales matching the ER verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated at lines 798-802 from ER 365: baseline fasting early morning, week 4, each cycle end, then every three to six months beyond three cycles, with hormones redrawn at the same hour. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER qualitative markers list (ER 382-388). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are present verbatim as qualitative_item_1 through qualitative_item_5. |
Issues 14/09/2026 06:06
Pass rate 100.00%. No issues found.